X
[{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Signet","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Signet Healthcare Partners Completes Growth Equity Investment in Juno Pharmaceuticals Corp.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Juno Pharmaceuticals Pty Ltd"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Juno Pharmaceuticals Receives Approval to Import Eptifibatide as Canadian Hospitals Continue to Grapple with Shortages of Critical Medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Peptide","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Juno Pharmaceuticals Pty Ltd"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa.
Lead Product(s):
Eptifibatide
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 30, 2023
Details:
Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio including Adrenaline Aguettant. Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and specifically with generics.
Lead Product(s):
Epinephrine
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Adrenaline Aguettant-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Signet
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Financing
February 24, 2022